Milestone Pharmaceuticals
Yahoo Finance • 29 days ago
Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval
As previously reported, TD Cowen upgraded Milestone Pharmaceuticals (MIST) to Buy from Hold with an $8 price target after Cardamyst nasal spray was approved by the FDA for the conversion of acute symptomatic episodes of paroxysmal supraven... Full story
Yahoo Finance • last month
MIST Hits A Milestone: FDA Approves First-Ever Self-Administered Nasal Spray For PSVT
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) has received FDA approval for its first commercial product, CARDAMYST nasal spray, for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhyth... Full story
Yahoo Finance • last month
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 30,000 option... Full story
Yahoo Finance • 2 months ago
Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects
Milestone Pharmaceuticals (NASDAQ:MIST) is one of the Canadian penny stocks to buy right now. On November 13, analysts at Jefferies reiterated a Hold rating on Milestone Pharmaceuticals (NASDAQ: MIST) and raised the price target to $2 from... Full story
Yahoo Finance • 2 months ago
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
PDUFA Target Date of December 13, 2025 for CARDAMYST™ (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT) Promotional Launch Plans Set with Quick-Start Capability Upon Potential FDA Approval $82.6 million in Cash at... Full story
Yahoo Finance • 2 months ago
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
MONTREAL and CHARLOTTE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today an... Full story
Yahoo Finance • 3 months ago
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
MONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today ann... Full story
Yahoo Finance • 5 months ago
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST if Approved Public Offering Raised Tot... Full story
Yahoo Finance • 6 months ago
Milestone Pharmaceuticals Launches Public Offering To Support Etripamil Development
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) has initiated an underwritten public offering of its common shares, Series A and Series B warrants for purchasing common shares, and, for certain investors, pre-funded warrants in place of... Full story
Yahoo Finance • 6 months ago
Milestone Pharmaceuticals prices $52.5 million public offering
MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company with a market capitalization of $118 million, has priced its previously announced underwritten public offering at $1.50 per share, expected to r... Full story
Yahoo Finance • 6 months ago
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medic... Full story
Yahoo Finance • 6 months ago
Milestone Pharmaceuticals stock plunges on public offering announcement
Investing.com -- Milestone Pharmaceuticals Inc (NASDAQ:MIST) stock tumbled 30% after the company announced plans for an underwritten public offering of common shares and warrants. The biopharmaceutical company said it will offer common... Full story
Yahoo Finance • 6 months ago
Milestone Pharmaceuticals Announces Proposed Public Offering
MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the “Offering”) of its common sha... Full story
Yahoo Finance • 6 months ago
Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray
New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (Mi... Full story
Yahoo Finance • 7 months ago
Milestone Pharmaceuticals submits response to FDA for PSVT drug
MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a $109.52 million market cap biotech company trading at $1.65 per share, has submitted its response to the U.S. Food and Drug Administration’s Complete Response Letter rega... Full story
Yahoo Finance • 8 months ago
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq:... Full story
Yahoo Finance • 10 months ago
FDA Issues Complete Response Letter for Etripamil for PSVT
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmac... Full story
Yahoo Finance • 10 months ago
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for mid-2025 Milestone well-capitalized to com... Full story
Yahoo Finance • 2 years ago
Milestone Pharmaceuticals Refreshes Board of Directors
Milestone Pharmaceuticals Inc. – Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -... Full story
Yahoo Finance • 3 years ago
Individual investors account for 48% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 38%
Key Insights Significant control over Milestone Pharmaceuticals by individual investors implies that the general public has more power to influence management and governance-related decisions 50% of the business is held by the top 25 shar... Full story
